Bennett Lawrence Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Bennett Lawrence Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	$5.58M	Buy	44,380 +26,830	+153%	+$3.24M	1.81%	20
2015 Q3	$1.83M	Buy	+17,550	New	+$2.25M	0.58%	54
2013 Q4	–	Sell	-128,985	Closed	-$9.78M	–	101
2013 Q3	$9.78M	Buy	+128,985	New	+$10.3M	1.58%	23

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Bennett Lawrence Management's VRTX Position: Q4 2015 in Review

Bennett Lawrence Management increased its Vertex Pharmaceuticals (VRTX) stake by 153% in Q4 2015, buying an estimated $3.24M and bringing the position to 44,380 shares worth $5.58M. The position accounts for 1.81% of the portfolio, ranked #20.

Bennett Lawrence Management first reported a position in VRTX in Q3 2013 and has held it in 3 quarters since. The position peaked at $9.78M in Q3 2013. 518 funds tracked by Wall St. Rank hold VRTX as of Q4 2015.

Bennett Lawrence Management held 44,380 shares of Vertex Pharmaceuticals worth $5.58M as of Q4 2015.
Bennett Lawrence Management bought 26,830 Vertex Pharmaceuticals shares in Q4 2015, an estimated $3.24M.
Vertex Pharmaceuticals made up 1.81% of Bennett Lawrence Management's portfolio in Q4 2015, its #20 holding.
Bennett Lawrence Management first reported a position in Vertex Pharmaceuticals in Q3 2013 and has held it in 3 quarters since.
Bennett Lawrence Management's Vertex Pharmaceuticals position peaked at $9.78M in Q3 2013.
518 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2015.

Based on Bennett Lawrence Management's 13F filing for Q4 2015, filed 16 Feb 2016.